Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
The combination of potent HbA1c reduction, minimal hypoglycemia risk, and cardiovascular benefit makes these agents the preferred glucose-lowering option for most patients with type 2 diabetes
This is particularly important in certain inborn errors of metabolism and during periods of fasting when the body relies more heavily on fat for energy
Both compounds delivered in the same draw
Methodology This study is based on an online survey of 1,004 U.S
Retatrutide (LY3437943) is an investigational triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously
US$ 26.03
US$ 22.22
US$ 27.70
US$ 22.93
US$ 27.28
US$ 24.52
US$ 24.27
